Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Feb 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a medication called Tocilizumab, which is an antibody that targets the IL6 receptor, in patients who need to have a kidney transplant removed (called graft nephrectomy). After this surgery, many patients develop anti-HLA antibodies, which can make it difficult to have a second kidney transplant in the future. The researchers want to see if giving Tocilizumab just before or after the surgery can help reduce these antibodies and prevent serious infections that could occur after the procedure.

To participate in this trial, patients need to be adults who are planning to have their kidney transplant removed and are hoping for a future transplant. They should also be covered by social security. However, there are certain people who cannot join, such as those with previous kidney transplants that weren't removed or those who are pregnant or breastfeeding. Participants will receive either the medication or standard care and will be monitored for any complications or changes in their antibody levels over the next year. This study is currently recruiting participants, and being involved could contribute to important research that may help future kidney transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult recipients,
• • affiliated to the social security
• • requiring a graft nephrectomy, with a project to retransplantation
• Exclusion Criteria:
• • combined transplantations, PRA \>20%.
• • Patient under protective measures,
• • Rituximab used for immunosuppression induction
• • Previous transplants not removed,
• • Active infectious complications at graft nephrectomy, need for immunosuppressive treatments after graft nephrectomy,
• • Participation to another interventional studies using Rituximab, polyclonal antibodies, Eculizumab, or Tocilizumab.
• • adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision,
• • pregnancy or breastfeeding.